Sorrento Therapeutics, Inc. is a commercial and clinical-stage biopharmaceutical company developing therapies for cancer, autoimmune, inflammatory, viral and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex.
Transakcja zakończona: osiągnięto poziom stop:
Nov 16